Fig. 5

B1R expressed in HaCaT cells on a PAR2 background. Positive immunocytochemistry reaction for B1R was observed and displaying membrane and cytosolic localization in HaCaT keratinocytes after 24-h incubation with vehicle (control), PAR2 agonist SLIGKV-NH2 (100 mM) (a). Representative images displaying nuclear localization of p65 (green) and DAPI (blue) in HaCaT keratinocytes after 24-h incubation with vehicle, SLIGKV-NH2 (100 mM) (c). Western blot of HaCaT cells following treatment with vehicle (control), SLIGKV-NH2 (100 mM). Samples were probed with antibodies against B1R and tubulin (b). B1R mRNA levels were also significantly augmented (d). Pretreatment with the NF-κB inhibitor PDTC (25 μM) prevented SLIGKV-NH2-induced B1R expression (b, d). Values represent mean ± SEM; *P < 0.05; **P < 0.01 by the Student t test